3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
Temozolomide
4
Irinotecan
4
eribulin
2
Topotecan
2
LY2940680
2
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
surufatinib
1
sonidegib
1
soblidotin
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
palbociclib
1
omburtamab I-131
1
lenvatinib
1
iso-sulfan blue
1
dostarlimab
1
dinutuximab
1
copanlisib
1
cixutumumab
1
ceritinib
1
bempegaldesleukin
1
amino-acid, glucose, and electrolyte solution
1
abemaciclib
1
Vincristine
1
Pemetrexed
1
Nivolumab
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rhabdomyosarcoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts